busulfan + fludarabine + muromonab-cd3 + thiotepa

This is a combination regimen consisting of four agents—busulfan, fludarabine, muromonab-cd3, and thiotepa—used as a conditioning protocol prior to hematopoietic stem cell transplantation (HSCT). Each component has a distinct mechanism: - **Busulfan** is an alkylating agent that induces myeloablation by cross-linking DNA, leading to cell death in rapidly dividing hematopoietic cells. - **Fludarabine** is a purine analog that inhibits DNA synthesis and repair by interfering with DNA polymerase and ribonucleotide reductase activity. - **Muromonab-cd3** is a murine monoclonal antibody targeting the CD3 receptor on T lymphocytes; it causes rapid depletion of T cells via complement-mediated lysis and opsonization, providing potent immunosuppression[5]. - **Thiotepa** is another alkylating agent with both myeloablative and immunosuppressive properties; it can penetrate the blood-brain barrier[4]. This combination aims to achieve effective myeloablation (elimination of bone marrow cells) and profound immunosuppression to facilitate engraftment of donor stem cells while reducing the risk of graft rejection. The regimen may be used for malignant (e.g., acute myeloid leukemia) or non-malignant disorders requiring HSCT[1][2][4]. Muromonab-cd3 specifically adds targeted T-cell depletion for enhanced prevention of graft rejection.